Gilead Sciences Inc

Gilead develops and sells antiviral medicines, with major franchises in HIV treatment (Biktarvy, Descovy), hepatitis C therapeutics, and oncology. The company generates most revenue from HIV medications, which patients take long-term for viral suppression. Gilead also sells COVID-19 treatment Veklury and is developing therapies for liver disease and cancer. The business model relies on specialty pharmaceuticals with high barriers to generic competition.

Gilead trades at relatively low P/E multiples reflecting concerns about HIV franchise competition and declining hepatitis C sales. The company generates strong free cash flow from its established HIV products, with growth depending on newer HIV formulations and oncology programs. Key risks include patent expirations, competitive pressure from GlaxoSmithKline and Johnson & Johnson in HIV, and execution in cell therapy following the Kite acquisition. The stock offers dividend income while investors wait for pipeline development.

In HIV treatment, GlaxoSmithKline/ViiV Healthcare (long-acting injectables) and Johnson & Johnson represent growing threats. For hepatitis C, AbbVie competed intensely though the market has shrunk significantly. In oncology, particularly CAR-T cell therapy, Gilead competes with Bristol Myers Squibb and Novartis. Generic drug manufacturers pose long-term risks as patents expire on older HIV medications.

Gilead initiated its dividend in 2015 and has grown it modestly since then, though not consistently year-over-year. The company maintains a conservative payout ratio around 40% of earnings, preserving cash for business development deals and pipeline investment. Management balances dividends with share repurchases and occasional large acquisitions, as seen with the $12 billion Immunomedics purchase. The dividend provides steady income while Gilead invests in growth areas beyond HIV.

GILD last closed at $138.26, up 0.11% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $93.37 and a high of $157.29. The current price represents 70% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Among 37 analysts covering GILD, the consensus rating is Strong Buy — 30 rate it a buy, 7 hold, and 0 sell. The average price target sits at $362.68, implying 162% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Gilead Sciences Inc generated $29.12B in revenue during fiscal year 2026, with $8.42B reaching the bottom line as net income. The net profit margin of 28.9% is strong by most industry standards.

GILD trades at a P/E ratio of 20.01 on trailing earnings of $6.78 per share. That's roughly in line with the broader market average of ~20-25x. Comparing this multiple against Biotechnology sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: +10.87% (3M), +22.77% (6M), +26.53% (1Y), +13.70% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether GILD is outperforming or lagging the broader market.